Apellis Pharmaceuticals Inc

Common Name

Apellis Pharmaceuticals

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

705

Ticker

APLS

Exchange

NASDAQ/NGS

Website

apellis.com

Description

Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medi... Show more

Financial Statements of Apellis Pharmaceuticals

Below are the financial statements of Apellis Pharmaceuticals, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	411.29^a	351.19^a
Accounts receivable	264.93^a	206.44^a
Inventory	81.4^a	146.36^a
Prepaid assets	18.37^a	38.82^a
Restricted cash	1.32^a	1.11^a
Other current assets	11.64^a	22.41^a
Total current assets	788.95^a	766.33^a
Non-current assets	—	—
Right-of-use assets	16.08^a	16.75^a
Property and equipment, net	2.95^a	4.35^a
Long-term inventory	75.71^a	0^a
Other assets	1.35^a	1.31^a
Total assets	885.05^a	788.73^a
Current liabilities	—	—
Accounts payable	38.57^a	37.52^a
Accrued expenses	140.18^a	127.81^a
Current portion of development liability	0^a	75.83^a
Current portion of lease liabilities	6.75^a	6.44^a
Total current liabilities	185.51^a	247.59^a
Long-term liabilities	—	—
Long-term development liability	0^a	239.82^a
Long-term credit facility	359.49^a	0^a
Convertible senior notes	93.34^a	93.03^a
Lease liabilities	10.2^a	11.45^a
Other liabilities	7.97^a	2.31^a
Liabilities and stockholders’ equity	—	—
Total liabilities	656.51^a	594.21^a
Commitments and contingencies	0^a	0^a
Stockholders’ equity	—	—
Preferred stock	0^a	0^a
Common stock	0.01^a	0.01^a
Additional paid-in capital	3,267.2^a	3,035.54^a
Accumulated other comprehensive loss	-3.31^a	-3.54^a
Accumulated deficit	-3,035.37^a	-2,837.49^a
Total stockholders’ equity	228.54^a	194.52^a
Total liabilities and stockholders’ equity	885.05^a	788.73^a

Verified Sources Behind Apellis Pharmaceuticals’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Apellis Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.

a. Apellis Pharmaceuticals's 10-K 2024

Trace every data point back to Apellis Pharmaceuticals’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Apellis Pharmaceuticals Inc

Financial Statements of Apellis Pharmaceuticals

Verified Sources Behind Apellis Pharmaceuticals’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

ACADIA Pharmaceuticals Inc

Halozyme Therapeutics Inc

PTC Therapeutics Inc

Madrigal Pharmaceuticals Inc

Ultragenyx Pharmaceutical Inc

Cytokinetics Inc